NewLimit, a longevity startup, has raised $435 million in funding. The company, which is reportedly working on reversing cellular aging, is said to be valued at $3.1 billion and is preparing for its first clinical trial, with some reports specifying that the trials will involve the liver. The funding is part of a Series C round, with the company's valuation having tripled.